Early Diagnosis and Treatment of Rheumatoid Arthritis

Understanding Rheumatoid Arthritis

A recent review highlights the importance of early diagnosis and prompt, goal-oriented treatment for rheumatoid arthritis (RA) in enhancing patient outcomes. Rheumatoid arthritis is an inflammatory autoimmune disorder characterized by pain, swelling, and deformity across multiple joints. It occurs when the immune system mistakenly attacks the joint linings. In some cases, it can also impact other organs, including the skin, eyes, lungs, heart, and blood vessels. Approximately 1% of Canadians are affected by this disease, with women being 2 to 3 times more likely to develop it than men.

Historical Perspective on Prognosis

Historically, the prognosis for rheumatoid arthritis was considered poor, often resulting in progressive joint degeneration, disability, and decreased life expectancy. Treatment typically began after significant disease progression, and regular monitoring of treatment efficacy was uncommon. However, advancements in treatment approaches, particularly with the use of disease-modifying anti-rheumatic drugs (DMARDs), have made it possible for many patients to achieve disease remission.

Insights from Recent Research

A paper published in The Lancet in June 2017 emphasizes the advantages of early diagnosis and treatment initiation within three to six months of joint swelling onset. This timely intervention is crucial for minimizing joint damage and attaining disease remission. The treat-to-target strategy involves establishing specific treatment goals, which may include achieving remission, reducing mortality or cardiovascular risks, and preventing joint damage.

Standard Treatment Protocols

Methotrexate, a commonly used DMARD, typically serves as the first-line treatment. Glucocorticoids may be added for short-term management if necessary. If the desired treatment outcomes are not achieved, other standard DMARDs can be considered. In cases where prognosis remains poor, biologics or targeted DMARDs, such as JAK inhibitors like tofacitinib and baricitinib, may be appropriate alternatives.

Role of Biologics in Treatment

The review also outlines the effectiveness of biologics in managing rheumatoid arthritis. Biologics are complex molecules derived from natural sources or genetically engineered organisms. Several antibodies, including infliximab, adalimumab, and etanercept, have shown improved outcomes when combined with methotrexate compared to methotrexate alone.

Emerging Therapeutics

The review further explores new classes of drugs, particularly Janus kinase (JAK) inhibitors such as tofacitinib and baricitinib. These medications target key signaling pathways involved in inflammation and have demonstrated safety and efficacy in clinical trials. Tofacitinib is approved for use in various countries, including the USA, Canada, Russia, and Switzerland, often in combination with methotrexate for patients with moderate to severe active rheumatoid arthritis.

Biosimilars and Their Impact

Several biosimilars, which are comparable to existing biologics like infliximab and etanercept, have been approved or are under development. One notable example is CT-P13, which matches the efficacy and safety of infliximab. However, the transition from biologics to biosimilars has been gradual, particularly in the USA and Canada, despite their generally lower costs.

Preventive Strategies for At-Risk Individuals

Lastly, the review discusses the potential for preventing the onset of full-blown rheumatoid arthritis in individuals exhibiting early symptoms, such as joint swelling or pain, or the presence of specific antibodies in their blood. Treatments including methotrexate, intra-articular steroids, and specific biologics have been shown to delay or even prevent the disease in these individuals.

Conclusion

In conclusion, the review emphasizes the significance of early diagnosis and the initiation of DMARD therapy in improving the prognosis for rheumatoid arthritis patients. Key strategies include prompt treatment initiation, regular assessments, and setting clear treatment goals, all of which contribute to favorable outcomes and potential remission for most patients.

References

The Arthritis Society. Rheumatoid Arthritis. http://arthritis.ca/understand-arthritis/types-of-arthritis/rheumatoid-arthritis. Accessed July 16, 2017.
Burmester GR, Pope JE. Novel treatment strategies in rheumatoid arthritis. Lancet. 2017 Jun 10;389(10086):2338-2348. doi: 10.1016/S0140-6736(17)31491-5. Review. PubMed PMID: 28612748.